LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $46.60 Average Target Price from Analysts

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $46.60.

Several equities research analysts recently weighed in on the company. Piper Sandler began coverage on LENZ Therapeutics in a report on Monday, April 14th. They issued an "overweight" rating and a $51.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday, May 8th.

Institutional Investors Weigh In On LENZ Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of LENZ Therapeutics during the 4th quarter worth approximately $46,000. Tower Research Capital LLC TRC grew its position in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after buying an additional 1,151 shares during the period. Virtus ETF Advisers LLC bought a new stake in shares of LENZ Therapeutics in the 4th quarter valued at about $67,000. Banque Transatlantique SA acquired a new stake in shares of LENZ Therapeutics in the 1st quarter valued at approximately $119,000. Finally, GAMMA Investing LLC raised its position in shares of LENZ Therapeutics by 5,254.1% in the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock valued at $150,000 after acquiring an additional 5,727 shares during the period. Institutional investors own 54.32% of the company's stock.

LENZ Therapeutics Price Performance

NASDAQ LENZ traded up $0.35 on Monday, hitting $33.40. 160,407 shares of the stock were exchanged, compared to its average volume of 314,349. The company's 50-day moving average price is $30.69 and its two-hundred day moving average price is $26.70. LENZ Therapeutics has a 52-week low of $16.53 and a 52-week high of $38.93. The company has a market capitalization of $940.21 million, a price-to-earnings ratio of -18.87 and a beta of 0.42.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. Equities analysts predict that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.